parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in sertoli cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 16	0.91
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6896

KCNK13 in dopamine neurons, braak+0.28 (p 0.459) → +0.08 (p 0.839)receipt 6903
KCNK13 in microglia, braak-0.43 (p 0.243) → -0.49 (p 0.183)receipt 6902

receipt 6903: KCNK13 in dopamine neurons, braak

power: full sample +0.18 (p 0.465, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.482, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.455, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.34, sign flips 0; without severely affected donors +0.18 (p 0.465, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KCNK13 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6902: KCNK13 in microglia, braak

power: full sample -0.34 (p 0.170, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.29 (p 0.246, n 18). could be the mix.
skeptic: leave-one-out range -0.48 to -0.26, sign flips 0; without severely affected donors -0.34 (p 0.170, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KCNK13 in microglia.

case closed: nothing better to follow up.

loading the receipts